Search research articles
Contact Us
Filters
Showing results (11-20 of 42) with videos related to
Page
of 5
Sort By:
The Journal of Antimicrobial Chemotherapy
|
March 25, 2025
Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018-21
John J Schellenberg, Heather J Adam, Melanie R Baxter, et al.
The Journal of Antimicrobial Chemotherapy
|
February 10, 2022
PCV-15 and PPSV-23 coverage of invasive and respiratory tract Streptococcus pneumoniae, including MDR and XDR isolates: CANWARD 2007-20
Alyssa R Golden, Melanie Baxter, Heather J Adam, et al.
Vaccine
|
August 29, 2021
Whole genome characterization of Streptococcus pneumoniae from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007-2018
Alyssa R Golden, Heather J Adam, Melanie Baxter, et al.
Journal of Clinical Microbiology
|
September 8, 2021
Use of Fosfomycin Etest To Determine <i>In Vitro</i> Susceptibility of Clinical Isolates of <i>Enterobacterales</i> Other than Escherichia coli, Nonfermenting Gram-Negative Bacilli, and Gram-Positive Cocci
James A Karlowsky, Melanie R Baxter, Alyssa R Golden, et al.
The Journal of Antimicrobial Chemotherapy
|
May 2, 2023
Analysis of MDR in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-2020
Heather J Adam, James A Karlowsky, Melanie R Baxter, et al.
The Journal of Antimicrobial Chemotherapy
|
August 11, 2021
ESBL-positive Escherichia coli and Klebsiella pneumoniae isolates from across Canada: CANWARD surveillance study, 2007-18
James A Karlowsky, Andrew Walkty, Alyssa R Golden, et al.
The Journal of Antimicrobial Chemotherapy
|
May 2, 2023
Comparison of PCV10, PCV13, PCV15, PCV20 and PPSV23 vaccine coverage of invasive Streptococcus pneumoniae isolate serotypes in Canada: the SAVE study, 2011-20
John J Schellenberg, Heather J Adam, Melanie R Baxter, et al.
One Health (Amsterdam, Netherlands)
|
May 25, 2026
Seasonal and spatial dynamics of <i>Enterococcus</i> and antimicrobial resistance in a one health dairy ecosystem in Western Canada
Shawn Hoogstra, Cassandra Klaas, Jillaine Kuelker, et al.
Diagnostic Microbiology and Infectious Disease
|
December 20, 2020
Comparison of PCV-10 and PCV-13 vaccine coverage for invasive pneumococcal isolates obtained across Canadian geographic regions, SAVE 2011 to 2017
Rachel K Hink, Heather J Adam, Alyssa R Golden, et al.
The Journal of Antimicrobial Chemotherapy
|
August 11, 2021
Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing Escherichia coli collected from Canadian hospitals: CANWARD 2007-18
Alyssa R Golden, James A Karlowsky, Andrew Walkty, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 42) with videos related to
Sort By:
Page
of 5
The Journal of Antimicrobial Chemotherapy
|
March 25, 2025
Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018-21
John J Schellenberg, Heather J Adam, Melanie R Baxter, et al.
The Journal of Antimicrobial Chemotherapy
|
February 10, 2022
PCV-15 and PPSV-23 coverage of invasive and respiratory tract Streptococcus pneumoniae, including MDR and XDR isolates: CANWARD 2007-20
Alyssa R Golden, Melanie Baxter, Heather J Adam, et al.
Vaccine
|
August 29, 2021
Whole genome characterization of Streptococcus pneumoniae from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007-2018
Alyssa R Golden, Heather J Adam, Melanie Baxter, et al.
Journal of Clinical Microbiology
|
September 8, 2021
Use of Fosfomycin Etest To Determine <i>In Vitro</i> Susceptibility of Clinical Isolates of <i>Enterobacterales</i> Other than Escherichia coli, Nonfermenting Gram-Negative Bacilli, and Gram-Positive Cocci
James A Karlowsky, Melanie R Baxter, Alyssa R Golden, et al.
The Journal of Antimicrobial Chemotherapy
|
May 2, 2023
Analysis of MDR in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-2020
Heather J Adam, James A Karlowsky, Melanie R Baxter, et al.
The Journal of Antimicrobial Chemotherapy
|
August 11, 2021
ESBL-positive Escherichia coli and Klebsiella pneumoniae isolates from across Canada: CANWARD surveillance study, 2007-18
James A Karlowsky, Andrew Walkty, Alyssa R Golden, et al.
The Journal of Antimicrobial Chemotherapy
|
May 2, 2023
Comparison of PCV10, PCV13, PCV15, PCV20 and PPSV23 vaccine coverage of invasive Streptococcus pneumoniae isolate serotypes in Canada: the SAVE study, 2011-20
John J Schellenberg, Heather J Adam, Melanie R Baxter, et al.
One Health (Amsterdam, Netherlands)
|
May 25, 2026
Seasonal and spatial dynamics of <i>Enterococcus</i> and antimicrobial resistance in a one health dairy ecosystem in Western Canada
Shawn Hoogstra, Cassandra Klaas, Jillaine Kuelker, et al.
Diagnostic Microbiology and Infectious Disease
|
December 20, 2020
Comparison of PCV-10 and PCV-13 vaccine coverage for invasive pneumococcal isolates obtained across Canadian geographic regions, SAVE 2011 to 2017
Rachel K Hink, Heather J Adam, Alyssa R Golden, et al.
The Journal of Antimicrobial Chemotherapy
|
August 11, 2021
Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing Escherichia coli collected from Canadian hospitals: CANWARD 2007-18
Alyssa R Golden, James A Karlowsky, Andrew Walkty, et al.
Page
of 5